In a study that explored the use of convalescent plasma therapy from donors as a form of treatment in severe COVID-19, ELISA was used to assess the neutralizing activity of the RBD-specific IgM and IgG antibodies found in the donor convalescent plasma.64 This evidence concerns the gene CD40LG and COVID-19.